NEFL and Alzheimer disease: According to the work of Steinacker et al. (2018) on 74 bvFTD cases, serum NFL enables the discrimination of this condition from neurologically healthy controls, patients with MCI, and patients with AD with sensitivities of 91, 74, and 74%, respectively, and specificities of 79, 74, and 58%, respectively.